Home/Filings/4/0000950170-24-118424
4//SEC Filing

von Moltke Lisa 4

Accession 0000950170-24-118424

CIK 0001609809other

Filed

Oct 28, 8:00 PM ET

Accepted

Oct 29, 6:33 PM ET

Size

9.8 KB

Accession

0000950170-24-118424

Insider Transaction Report

Form 4
Period: 2024-10-27
von Moltke Lisa
See Remarks
Transactions
  • Sale

    Common Stock

    2024-10-28$0.69/sh4,334$2,99130,423 total
  • Exercise/Conversion

    Restricted Stock Units

    2024-10-2713,7440 total
    Common Stock (13,744 underlying)
  • Exercise/Conversion

    Common Stock

    2024-10-27+13,74434,757 total
Footnotes (4)
  • [F1]On February 3, 2023, the reporting person was granted an award of 27,489 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,745 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,744 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date.
  • [F2]Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.
  • [F3]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on July 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  • [F4]The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.7011, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file

Issuer

Seres Therapeutics, Inc.

CIK 0001609809

Entity typeother

Related Parties

1
  • filerCIK 0001808592

Filing Metadata

Form type
4
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 6:33 PM ET
Size
9.8 KB